https://www.marketscreener.com/quote/stock/SPYRE-THERAPEUTICS-INC-27114072/news/Aeglea-BioTherapeutics-Inc-Announces-Achievement-of-Primary-Endpoint-in-Phase-3-Study-of-Pegzilarg-37246681/?utm_source=telegram&utm_medium=social&utm_campaign=share